XmAb5871

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

IgG4-RD

Conditions

IgG4-RD

Trial Timeline

Mar 1, 2016 → Dec 1, 2017

NCT ID

NCT02725476

About XmAb5871

XmAb5871 is a phase 2 stage product being developed by Xencor for IgG4-RD. The current trial status is completed. This product is registered under clinical trial identifier NCT02725476. Target conditions include IgG4-RD.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02867098	Phase 1	Completed	Jul 1, 2016	Oct 21, 2016	Healthy Volunteers
NCT02725476	Phase 2	Completed	Mar 1, 2016	Dec 1, 2017	IgG4-RD